Vaxcyte PCVX Income Statement (2019-2026)

NASDAQ PCVX
$68.62 +2.26 (+3.41%)
At close: Nov 11, 2026 · 4:00 PM EST
Reported Financials

Vaxcyte Quarterly Income Statement

Periods 31 quarters
Latest Sep 2026

Vaxcyte reported net income of -$285.08M for the quarter ended Sep 2026. This income statement covers 31 quarters of results from Mar 2019 through Sep 2026, standardized by Business Quant from the company’s SEC filings.

Income StatementIncome Statement Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026 Sep2026
Operating items
Research & DevelopmentR&D
23.07M31.68M38.47M47.68M51.63M58.08M72.69M97.42M104.15M94.59M131.51M116.94M133.61M148.13M194.18M209.93M242.06M312.78M267.85M270.33M
Selling, General & AdministrativeSG&A
6.77M7.54M9.42M10.90M11.95M13.11M14.46M15.61M17.53M19.89M21.47M22.99M28.56M32.66M32.04M32.45M32.22M33.07M34.93M37.95M
Other Operating ExpensesOther Opex
23.00M75.00M
Operating ExpensesOpex
29.85M39.22M47.89M58.58M86.57M71.19M87.15M113.03M196.68M114.47M152.98M139.92M162.17M180.79M226.22M242.38M274.28M345.85M302.78M308.27M
Operating IncomeOp. Inc
-29.85M-39.22M-47.89M-58.58M-86.57M-71.19M-87.15M-113.03M-196.68M-114.47M-152.98M-139.92M-162.17M-180.79M-226.22M-242.38M-274.28M-345.85M-302.78M-308.27M
Non-operating items
Non Operating Interest Expenses
0.00M
Gains (Losses) on Sale of Assets & InvestmentsGains on Sales
0.02M0.03M0.00M
Interest & Investment IncomeInt & Inv Inc
0.10M0.13M0.40M1.19M6.63M10.39M16.45M18.50M17.57M21.67M23.81M28.06M36.46M32.94M31.07M29.26M26.45M26.61M25.76M23.19M
Other Non Operating IncomeOther Non Op Inc.
1.28M0.24M-1.73M-0.69M11.25M10.41M18.70M20.59M-46.83M-2.21M0.47M8.74M-11.37M7.14M28.57M0.29M1.33M-1.38M-7.28M-11.98M
Non Operating IncomeNon Op. Inc.
1.28M0.24M-0.65M0.66M8.52M10.73M18.81M20.36M15.88M19.45M24.28M36.80M25.09M40.08M59.65M29.55M27.78M25.23M18.48M11.21M
Net income details
EBIT
-29.85M-39.22M-47.89M-58.58M-86.57M-71.19M-87.15M-113.03M-196.68M-114.47M-152.98M-139.92M-162.17M-180.79M-226.22M-242.38M-274.28M-345.85M-302.78M-308.27M
EBT
-29.75M-39.09M-47.49M-57.39M-79.94M-60.80M-70.70M-94.53M-179.11M-92.81M-129.17M-111.87M-125.71M-147.86M-195.15M-213.12M-247.83M-319.24M-277.02M-285.09M
Income After Tax
-29.75M-39.09M-47.49M-57.39M-79.94M-60.80M-70.70M-94.53M-179.11M-92.81M-129.17M-111.87M-125.71M-147.86M-195.15M-213.12M-247.83M-319.24M-277.02M-285.09M
Income from Continuing OperationsIncome (Continuing)
-29.75M-39.09M-47.49M-57.39M-79.94M-60.80M-70.70M-94.53M-179.11M-92.81M-129.17M-111.87M-125.71M-147.86M-195.15M-213.12M-247.83M-319.24M-277.02M-285.09M
Consolidated Net IncomeConsol Net Inc.
-29.75M-39.09M-47.49M-57.39M-79.94M-60.80M-70.70M-94.53M-179.11M-92.81M-129.17M-111.87M-125.71M-147.86M-195.15M-213.12M-247.83M-319.24M-277.02M-285.09M
Income towards Parent CompanyParent Net Inc
-28.56M-38.99M-48.53M-57.92M-78.05M-60.46M-68.34M-92.66M-180.80M-95.02M-128.70M-103.12M-137.08M-140.72M-166.57M-212.83M-246.51M-320.62M-284.30M-297.06M
Net Income towards Common StockholdersNet Income
-28.56M-38.99M-48.53M-57.92M-78.05M-60.46M-68.34M92.66M-623.73M-95.02M-128.70M-103.12M-137.08M-140.72M-166.57M-212.83M-246.51M-320.62M-284.30M-297.06M
Additional items
EPS (Basic)
-0.55-0.68-0.80-0.93-1.20-0.70-0.700.91-6.42-0.85-1.10-0.83-1.12-1.04-1.22-1.56-1.81-2.30-1.97-1.99
EPS (Diluted)
-0.55-0.68-0.80-0.93-1.20-0.70-0.700.91-6.42-0.85-1.10-0.83-1.12-1.04-1.22-1.56-1.81-2.30-1.97-1.99
Shares Outstanding
51.92M57.55M60.82M61.99M64.88M86.21M98.06M101.67M97.16M111.69M117.26M123.69M122.00M135.69M136.03M136.20M136.09M139.51M144.49M148.91M
Shares Outstanding (Diluted)Shares Outstanding (Dil.)
51.92M57.55M60.82M61.99M64.88M86.21M98.06M101.67M97.16M111.69M117.26M123.69M122.00M135.69M136.03M136.20M136.09M139.51M144.49M148.91M
Shares Outstanding (Entity)Shares Outstanding (Entity.)
53.03M56.50M58.62M60.57M64.88M80.64M93.81M95.10M95.36M108.76M110.58M124.43M124.89M128.94M129.82M130.03M131.06M144.31M144.79M149.30M
EBITDA
-29.39M-38.64M-47.28M-57.89M-85.61M-70.48M-86.40M-112.22M-195.79M-113.47M-151.63M-138.14M-159.31M-177.84M-223.34M-239.32M-266.79M-342.90M-299.78M-298.39M
Interest ExpensesInt Expense
0.00M

Vaxcyte Income Statement API

Pull Vaxcyte's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/statements?ticker=PCVX&statement=IS&frequency=Quarter&period=all&api_key=YOUR_API_KEY